Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 1135

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 7A
Chunk 1135
---
 by us regarding accounting, internal accounting controls or
reports which raise material issues regarding our financial statements or accounting policies;

●monitoring
compliance on a quarterly basis and, if any non-compliance is identified, immediately taking all action necessary to rectify such non-compliance
or otherwise causing compliance; and

●reviewing
and approving all payments made to our existing shareholders, executive officers or directors and their respective affiliates. Any payments
made to members of our audit committee will be reviewed and approved by our board of directors, with the interested director or directors
abstaining from such review and approval.

Compensation
Committee Interlocks and Insider Participation

None
of our executive officers currently serves, and in the past year has not served, as a member of the compensation committee of any entity
that has one or more executive officers serving on our board of directors.

Code
of Ethics

We
have adopted a Code of Ethics applicable to our directors, officers and employees. A copy of the Code of Ethics will be provided without
charge upon request from us. We intend to disclose any amendments to or waivers of certain provisions of our Code of Ethics in a Current
Report on Form 8-K.

Trading
Policies

The
Company has adopted an insider trading policy that governs the purchase, sale, and/or other transactions of our securities by our directors,
officers and employees. A copy of our insider trading policy is filed as Exhibit 19.1 to this Annual Report on Form 10-K for the fiscal
year ended December 31, 2024. In addition, with regard to the Company’s trading in its own securities, it is the Company’s
policy to comply with the federal securities laws and the applicable exchange listing requirements.

Availability
of Documents

We
have filed a copy of our Code of Ethics and our audit committee charter as exhibits to the registration statement relating to our IPO.
You can review these documents by accessing our public filings at the SEC’s website at www.sec.gov. We intend to disclose any amendments
to or waivers of certain provisions of our Code of Ethics in a Current Report on Form 8-K.

Section
16(a) Beneficial Ownership Reporting Compliance 

Section
16(a) of the Exchange Act, requires our executive officers, directors and persons who beneficially own more than 10% of a registered
class of our equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of the ordinary
shares of the Company and other equity securities.